A Bayesian stopping rule for a single arm study: With a case study of stem cell transplantation.

Continuous monitoring of treatment failures is an important issue in clinical studies of a single experimental treatment for high risk therapy such as hematopoietic stem cell transplantation. The sequential probability ratio test (SPRT) of Wald in 1947 and various alternative stopping rules have been proposed for sequential monitoring of adverse events. It is natural to use prior information to improve stopping rules and statistical analysis. A Bayesian stopping rule is developed and applied to an example of an umbilical cord blood transplant study performed at the University of Minnesota. Two strata, based on the number of nucleated cells per kg recipient body weight (the 'dose') are monitored separately and different rules are constructed for each stratum using different prior distributions. It is believed that patients in the lower dose group have a greater chance of graft failure than those in the higher dose group. A program, written in R, is also presented for calculating the stopping rule using the prior beliefs. The program is an improvement upon existing programs and it can be used for larger studies.

[1]  Todd E DeFor,et al.  Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  A. Goldman Issues in designing sequential stopping rules for monitoring side effects in clinical trials. , 1987, Controlled clinical trials.

[3]  J. Wagner,et al.  Umbilical-cord blood transplantation for the treatment of cancer , 2003, Nature Reviews Cancer.

[4]  M R Conaway,et al.  Bivariate sequential designs for phase II trials. , 1995, Biometrics.

[5]  J Wagner,et al.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. , 2002, Blood.

[6]  M. Degroot Optimal Statistical Decisions , 1970 .

[7]  A I Goldman,et al.  Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm. , 2001, Statistics in medicine.

[8]  P F Thall,et al.  Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.

[9]  J. Bryant,et al.  Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.

[10]  Peter F Thall,et al.  Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials , 2002, Biometrics.